Literature DB >> 3680790

Coexistent pulmonary and portal hypertension: morphologic and clinical features.

B S Edwards1, E K Weir, W D Edwards, J Ludwig, R K Dykoski, J E Edwards.   

Abstract

Patients with portal hypertension of varying etiology may develop pulmonary artery hypertension. In the present autopsy study, pulmonary and hepatic tissue was studied in 12 patients in whom pulmonary and portal hypertension coexisted. Plexogenic pulmonary arteriopathy was present in 10 patients, 7 of whom had coexistent thromboembolic lesions. One patient had isolated medial hypertrophy, which may be an early stage in the plexogenic category, whereas isolated thromboembolic pulmonary vascular disease was observed in one subject. Hepatic disease was consistent with alcoholic cirrhosis in seven patients, cryptogenic cirrhosis in four and extrahepatic portal hypertension without cirrhosis in one. Thrombocytopenia was present in all 10 patients whose platelet count was determined. This study suggests that pulmonary hypertension associated with portal hypertension commonly has a plexogenic appearance on histologic examination. However, thrombosis (whether embolic or in situ) may also contribute to vascular obstruction.

Entities:  

Mesh:

Year:  1987        PMID: 3680790     DOI: 10.1016/s0735-1097(87)80123-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  26 in total

1.  Hepatopulmonary syndromes.

Authors:  M J Krowka
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension.

Authors:  P Egermayer; G I Town; A J Peacock
Journal:  Thorax       Date:  1999-02       Impact factor: 9.139

4.  Acute right ventricular failure after orthotopic liver transplantation.

Authors:  Rohan M Goswami; Rami N Khouzam
Journal:  Ann Transl Med       Date:  2018-01

5.  Effectiveness of phosphodiesterase-5 inhibitor therapy for portopulmonary hypertension.

Authors:  Jolene H Fisher; Sindhu R Johnson; Cathy Chau; Amie T Kron; John T Granton
Journal:  Can Respir J       Date:  2014-12-18       Impact factor: 2.409

6.  Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension.

Authors:  Yu Yamashita; Ichizo Tsujino; Takahiro Sato; Asuka Yamada; Taku Watanabe; Hiroshi Ohira; Masaharu Nishimura
Journal:  World J Hepatol       Date:  2014-11-27

7.  Pulmonary hypertension associated with primary biliary cirrhosis in the absence of portal hypertension: a case report.

Authors:  E M Yoshida; S R Erb; D N Ostrow; D R Ricci; C H Scudamore; G Fradet
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

8.  Portopulmonary hypertension.

Authors:  Sarfraz Saleemi
Journal:  Ann Thorac Med       Date:  2010-01       Impact factor: 2.219

Review 9.  Pulmonary complications of hepatic diseases.

Authors:  Salim R Surani; Yamely Mendez; Humayun Anjum; Joseph Varon
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

Review 10.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.